Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases
- PMID: 20200515
- PMCID: PMC4120751
- DOI: 10.1038/clpt.2010.2
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases
Abstract
Members of the nuclear receptor (NR) superfamily of ligand-activated transcription factors are players of substantial relevance in the regulation of hepatic gene expression. NRs direct normal physiology and metabolism, adaptations to liver disease, and responses to inflammation and toxins.They also contribute to the regenerative response. In this review, we summarize currently available experimental and clinical data, focusing on the role of NRs in cholestasis and nonalcoholic fatty liver disease (NAFLD). We also highlight the potential of NRs as targets for safe and effective therapeutic interventions.
Similar articles
-
Nuclear receptors in acute and chronic cholestasis.Dig Dis. 2015;33(3):357-66. doi: 10.1159/000371688. Epub 2015 May 27. Dig Dis. 2015. PMID: 26045270 Review.
-
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.Semin Liver Dis. 2016 Feb;36(1):69-86. doi: 10.1055/s-0036-1571296. Epub 2016 Feb 12. Semin Liver Dis. 2016. PMID: 26870934 Review.
-
Novel therapeutic targets for cholestatic and fatty liver disease.Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6. Gut. 2022. PMID: 34615727 Free PMC article. Review.
-
Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.Chem Biol Interact. 2010 Mar 30;184(3):376-87. doi: 10.1016/j.cbi.2010.01.008. Epub 2010 Jan 15. Chem Biol Interact. 2010. PMID: 20079722
-
Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Annu Rev Pharmacol Toxicol. 2016;56:605-626. doi: 10.1146/annurev-pharmtox-010715-103209. Annu Rev Pharmacol Toxicol. 2016. PMID: 26738480 Free PMC article. Review.
Cited by
-
Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.Med Pharm Rep. 2024 Apr;97(2):111-119. doi: 10.15386/mpr-2628. Epub 2024 Apr 25. Med Pharm Rep. 2024. PMID: 38746033 Free PMC article. Review.
-
In-depth proteomic characterization of endogenous nuclear receptors in mouse liver.Mol Cell Proteomics. 2013 Feb;12(2):473-84. doi: 10.1074/mcp.M112.022319. Epub 2012 Nov 29. Mol Cell Proteomics. 2013. PMID: 23197792 Free PMC article.
-
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.Front Pharmacol. 2016 Sep 28;7:345. doi: 10.3389/fphar.2016.00345. eCollection 2016. Front Pharmacol. 2016. PMID: 27733832 Free PMC article.
-
Exposure to 2,4-dichlorophenoxyacetic acid induced PPARβ-dependent disruption of glucose metabolism in HepG2 cells.Environ Sci Pollut Res Int. 2018 Jun;25(17):17050-17057. doi: 10.1007/s11356-018-1921-6. Epub 2018 Apr 9. Environ Sci Pollut Res Int. 2018. PMID: 29633193
-
A network biology workflow to study transcriptomics data of the diabetic liver.BMC Genomics. 2014 Nov 15;15(1):971. doi: 10.1186/1471-2164-15-971. BMC Genomics. 2014. PMID: 25399255 Free PMC article.
References
-
- Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35. - PubMed
-
- Dasarathy S. Inflammation and liver. JPEN J Parenter Enteral Nutr. 2008;32:660–6. - PubMed
-
- Ramadori G, Moriconi F, Malik I, Dudas J. Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol Pharmacol. 2008;59 (Suppl 1):107–17. - PubMed
-
- Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol Res. 2008;58:129–36. - PubMed
-
- Downes M, Liddle C. Look Who’s Talking: Nuclear Receptors in the Liver and Gastrointestinal Tract. Cell Metabolism. 2008;7:195–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources